AstraZeneca Plc sold its 7.7% stake in Moderna Inc for more than $ 1 billion, according to The Times. Shares of the US biotechnology company have risen in price, controlling its breakthrough in coronavirus vaccine development. It is not yet clear who acquired the British company’s stake.
After the urgent approval in the USA at the end of last year, the shares of the American company have jumped by more than 100% so far. On Friday, trading closed 4.3% up to $ 154.8 per share.
AstraZeneca maintains its partnership with Moderna for other disease treatments and could sell its coronavirus vaccine on a commercial basis in the future if the virus becomes endemic, according to
Moderna, whose vaccine is approved for emergency use against COVID-19 in the United States and the European Union, said last week that it expects sales of $ 18.4 billion this year from the coronavirus vaccine alone.